Pfizer and Allergan announced plans to combine, creating a new global biopharmaceutical leader. The combination bolsters Pfizer's top-tier innovative biopharma business with Allergan's leadership positions in new therapeutic areas of growth. It also creates the world's leading established products business, positioning the combined company for global long-term growth. The transaction enhances the growth profile of the combined company by strengthening top-line growth potential and providing opportunities for synergies.
The document is a corporate presentation from Zenabis Global Inc. that provides disclaimers about the information contained within, noting that it does not constitute an offer or investment advice, contains forward-looking statements, and historical performance should not be relied upon as indicative of future results. The presentation includes information about the company, its facilities, production capacity, proposed regulatory changes, market trends, and competitive environment, but cautions that all forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. Recipients are advised to not rely on the information for investment decisions and to consider the company's other public disclosures.
The Health & Wellness market in the UK was valued at £23bn in 2020, an increase from £20.5bn in 2015. Total healthcare, wellness and fitness spending in the UK reached £209bn in 2020. Pure Restore Health provides innovative treatments and therapies utilizing the latest healthcare technologies to help people feel their best by addressing issues like chronic pain, injury recovery, athletic performance and more.
We’re creating better everyday products that combine cutting-edge plant-based materials and the latest sustainable designs so you can look good AND feel good!
Hemptown Spring 2019 Investor PresentationHemptown USA
From the rich soils of Southern Oregon's Emerald Triangle, Hemptown USA is producing some of the finest cannabinoid products in the world.
Hemptown USA’s toolkit is a unique one. Combined with our vertically integrated business model we are in firmly positioned to capitalize on a global market expected to exceed $22 billion by 2020.
Liberty Health Sciences Inc. is a Florida-based producer and retailer of medical cannabis products with over 300 employees. They operate a 190,000 square foot cultivation facility and have 26 dispensaries across the state. In their July 2020 investor presentation, Liberty highlighted their strong revenue growth, becoming profitable in August 2019, and plans for expansion of cultivation, manufacturing, and retail operations to capitalize on the large and growing medical cannabis market in Florida.
Tiziana Life Sciences presented an overview of their transformational immunotherapy platform enabling alternative routes of administration. Their proprietary technologies allow for oral, nasal, and inhalation delivery of antibodies, which currently require IV administration. They highlighted clinical progress including trials of their lead asset foralumab administered intranasally for progressive MS and COVID-19. Results demonstrated safety and positive clinical responses. Tiziana is also developing other pipeline assets and expanding their management team and scientific advisory board.
Liberty Health Sciences Inc. is a vertically integrated cannabis producer and retailer operating in Florida with over 300 employees, 26 dispensaries, 190,000 square feet of cultivation space, and has been profitable since August 2019. The document provides an overview of Liberty's operations, production capacity, product offerings, retail footprint in Florida, and financial information including quarterly revenue figures showing steady growth since Q3 2019.
The document is a corporate presentation from Zenabis Global Inc. that provides disclaimers about the information contained within, noting that it does not constitute an offer or investment advice, contains forward-looking statements, and historical performance should not be relied upon as indicative of future results. The presentation includes information about the company, its facilities, production capacity, proposed regulatory changes, market trends, and competitive environment, but cautions that all forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. Recipients are advised to not rely on the information for investment decisions and to consider the company's other public disclosures.
The Health & Wellness market in the UK was valued at £23bn in 2020, an increase from £20.5bn in 2015. Total healthcare, wellness and fitness spending in the UK reached £209bn in 2020. Pure Restore Health provides innovative treatments and therapies utilizing the latest healthcare technologies to help people feel their best by addressing issues like chronic pain, injury recovery, athletic performance and more.
We’re creating better everyday products that combine cutting-edge plant-based materials and the latest sustainable designs so you can look good AND feel good!
Hemptown Spring 2019 Investor PresentationHemptown USA
From the rich soils of Southern Oregon's Emerald Triangle, Hemptown USA is producing some of the finest cannabinoid products in the world.
Hemptown USA’s toolkit is a unique one. Combined with our vertically integrated business model we are in firmly positioned to capitalize on a global market expected to exceed $22 billion by 2020.
Liberty Health Sciences Inc. is a Florida-based producer and retailer of medical cannabis products with over 300 employees. They operate a 190,000 square foot cultivation facility and have 26 dispensaries across the state. In their July 2020 investor presentation, Liberty highlighted their strong revenue growth, becoming profitable in August 2019, and plans for expansion of cultivation, manufacturing, and retail operations to capitalize on the large and growing medical cannabis market in Florida.
Tiziana Life Sciences presented an overview of their transformational immunotherapy platform enabling alternative routes of administration. Their proprietary technologies allow for oral, nasal, and inhalation delivery of antibodies, which currently require IV administration. They highlighted clinical progress including trials of their lead asset foralumab administered intranasally for progressive MS and COVID-19. Results demonstrated safety and positive clinical responses. Tiziana is also developing other pipeline assets and expanding their management team and scientific advisory board.
Liberty Health Sciences Inc. is a vertically integrated cannabis producer and retailer operating in Florida with over 300 employees, 26 dispensaries, 190,000 square feet of cultivation space, and has been profitable since August 2019. The document provides an overview of Liberty's operations, production capacity, product offerings, retail footprint in Florida, and financial information including quarterly revenue figures showing steady growth since Q3 2019.
Virios Therapeutics is a clinical-stage biotechnology company focused on advancing novel, dual mechanism antiviral therapies to treat conditions associated with virally triggered or maintained immune responses, such as Fibromyalgia (“FM”). Immune responses related to the activation of tissue resident Herpes Simplex Virus-1 (“HSV-1”) have been postulated as a potential root cause triggering and/or sustaining chronic illnesses such as FM, irritable bowel disease (“IBS”), and chronic fatigue syndrome, all of which can be characterized by waxing and waning symptom flare-ups with no obvious etiology. Virios’ lead development candidate (“IMC-1”) is a novel, proprietary, fixed dose combination of famciclovir and celecoxib designed to synergistically suppress HSV-1 replication, with the end goal of reducing virally promoted disease symptoms.
Prophecy Resources Corp is developing the 600 MW Chandgana power plant in Mongolia to help meet the country's growing energy demand. The Chandgana project has over 1.2 billion tonnes of thermal coal resources and all necessary construction permits. The mine-mouth power plant is fully permitted and would be the first of its kind in Mongolia. It is strategically located near energy infrastructure and markets in China and Russia. Successful development of the 600 MW Phase I plant would help address Mongolia's current power shortages and reliance on imports.
The document is a presentation about representing the 600 MW Chandgana power plant project. It provides background information and disclaimers, noting that the information is subject to changes and updates. It warns that the communication of the presentation does not constitute a commitment to any transaction. It also contains forward-looking statements about the development and production of the power plant, but warns that actual results could differ due to risks and uncertainties in the mining industry.
Aridis Pharmaceuticals is a late-stage clinical development company, leading the creation of transformative, first-in-class anti-infectives for life-threatening viral and bacterial respiratory infections. The company’s lead drug candidate for acute pneumonia met the primary endpoint for its phase 2 clinical trial and the Company is now enrolling in a global phase 3 study. Its pipeline of novel mechanism antibacterial and antivirals, sprung from its proprietary discovery technology platforms, are designed to combat the growing public health threat of viral pandemics and antimicrobial resistant (AMR) bacteria. Its anti-toxin monoclonal antibody (mAb) approach is a proven mechanism of action and has shown preliminary trend toward efficacy as an adjunctive therapy in reducing acute pneumonia patients time in ICU as compared to the current standard of care, which is antibiotics. In addition to its phase 3 program, ARDS also has a phase 2 asset for the treatment of Bacteria HAP/VAP LPS 011. The company also has an on-going phase 2 clinical trial for the treatment of Cystic Fibrosis patients, a program funded by the Cystic Fibrosis Foundation for $7.5 million. Importantly, ARDS is also preparing to launch a Phase 1/2 clinical trial in the second half of 2021 with a self-administered broadly neutralizing mAb for emerging COVID-19 mutated variants. The expansion of COVID virus strain coverage, combined with the product's self-administered, at-home treatment modality, further differentiates the company's AR-712 COVID treatment offering.
CanniMed Therapeutics Inc. is a leader in the Canadian medical cannabis industry and the first mover in international markets. It has a 15-year history of growing pharmaceutical-grade cannabis and is well positioned for growth through new distribution channels in Canada, increasing production capacity, and pursuing exports to multiple countries. Recent developments include strong Q3 2017 results, entering Canada's first pharmacy distribution agreement, and commencing an expansion of its Cannabis Oils Facility.
This presentation discusses MedReleaf's position as the leading Canadian medical cannabis producer. It highlights MedReleaf's quality assurance processes, patient-centric approach, analytical operations, and ongoing innovation in producing premium cannabis. MedReleaf also discusses its market leading position with 82% market share, low production costs of $1.49 per gram, and high adjusted product contribution margins of 19%. The presentation outlines MedReleaf's expansion plans and growth opportunities in medical, new products, recreational, and international markets.
This presentation provides background information on Wellgreen Platinum Ltd. and its Wellgreen platinum project. Some key points:
- The information is for general informational purposes only and has not been independently verified. No representations or warranties are given as to the accuracy or completeness of the information.
- The presentation does not constitute an offer to sell securities or a solicitation to purchase securities.
- Certain statements are forward-looking and actual results may differ materially from expectations due to various risks and uncertainties.
- Technical information is based on technical reports prepared according to NI 43-101 standards and available on SEDAR. The technical reports should be read in their entirety.
Catasys provides an integrated virtual healthcare program called OnTrak that identifies and treats behavioral health conditions like substance abuse and depression. OnTrak uses predictive analytics to identify high-cost patients with behavioral health issues who rarely seek treatment. Patients enroll in a 52-week virtual treatment program with care coaching support. Studies show OnTrak significantly reduces medical costs and healthcare utilization for enrolled members. Catasys contracts with health plans to provide OnTrak and is paid a monthly fee per enrolled member.
The document is a presentation by Wellgreen Platinum Ltd providing information on its Wellgreen platinum project in Yukon, Canada. It summarizes key details of the project including its large scale polymetallic deposit containing nickel, copper, platinum group metals and other metals, the 2014 mineral resource estimate showing over 5 billion pounds of nickel and copper in the measured and indicated categories, and the positive 2015 preliminary economic assessment showing over $1.2 billion post-tax NPV with a 3.1 year payback. The presentation also outlines the company's strong financial position, management team with extensive experience in project development and operations, and district scale exploration potential.
This document provides background information on Wellgreen Platinum Ltd. and its Wellgreen platinum project. It discusses the large-scale polymetallic deposit containing platinum group metals (PGMs), nickel, copper, cobalt, and gold. The 2014 mineral resource estimate outlines 330 million tonnes of measured and indicated resources containing over 5.5 million ounces of PGMs and 4.9 billion pounds of nickel and copper. An 2015 preliminary economic assessment outlined an open-pit mine with average annual production of 209,000 ounces of PGMs and 128 million pounds of nickel and copper over a 16-year mine life at costs in the lowest quartile. The project benefits from excellent infrastructure and year-round operations in Canada's Yukon
The document provides background information on Wellgreen Platinum Ltd., a company developing the Wellgreen platinum group metals (PGM) project in Canada. It discusses the large-scale polymetallic deposit, noting its significant PGM component with a platinum to palladium ratio of 1:1 that is open pittable. The document also highlights the project's proximity to LNG power, lack of endangered species, strong government and First Nations support, and the critical nature and growing demand for its metals including nickel, PGMs, copper, gold, cobalt, and lithium which are used in batteries, aerospace, power plants, stainless steel, construction, electronics, green technology, and jewelry. It provides an overview of the
HR Compliance & Insurance Benefit Perspectives: What Employers Should Be Awar...Rea & Associates
Guidelines for employees are constantly changing but it’s important that businesses stay on top of mandates and regulations. What risks should organizations be informed about? Is your organization able to have varied insurance premiums for vaccinated vs. non-vaccinated employees?
Join Rea & Associates and Huntington Insurance for a deep dive into best practices for exposures, insurance perspectives, and vaccine mandates and regulations.
EcoStim is an oilfield services company providing well stimulation services in the US and Argentina. The presentation highlights:
1) EcoStim has secured multiple new contracts in 2017 anchoring a second crew in the US and a long-term contract in Argentina, positioning it for accelerated growth.
2) EcoStim trades at an attractive valuation compared to peers based on enterprise value per hydraulic horsepower.
3) EcoStim utilizes proprietary downhole diagnostic and predictive technologies to more efficiently target completion stages, reducing costs for customers.
The document is a prospectus for Atech Holdings Ltd regarding its acquisition of Fatfish Internet Pte Ltd and Fatfish Capital Ltd (together "Fatfish Group"). Key points include:
- Atech will acquire 100% of Fatfish Internet and 50% of Fatfish Capital for $18 million in new shares and options.
- Fatfish Group is an IT investments group focused on Southeast Asian startups and growth companies.
- The acquisition will change Atech's focus to IT investments in Southeast Asia and require it to recomply with ASX listing rules.
- Atech aims to grow Fatfish Group's existing e-commerce brands and assess new investment opportunities upon relisting.
Interpace Diagnostics provides molecular diagnostic tests and pathology services to evaluate cancer risk. The presentation discusses:
1) Interpace's product portfolio including tests that risk-stratify pancreatic cysts, Barrett's esophagus, and thyroid nodules.
2) Clinical evidence and guidelines supporting their tests, and growth in adoption and coverage by payers.
3) Financial highlights including recent funding raises, revenue growth, and progress reducing costs.
4) Drivers for continued growth including expanding sales force and strategic partnerships.
Aridis Pharmaceuticals is a late-stage clinical development company, leading the creation of transformative, first-in-class anti-infectives for life-threatening viral and bacterial respiratory infections. The company’s lead drug candidate for acute pneumonia met the primary endpoint for its phase 2 clinical trial and the Company is now enrolling in a global phase 3 study. Its pipeline of novel mechanism antibacterial and antivirals, sprung from its proprietary discovery technology platforms, are designed to combat the growing public health threat of viral pandemics and antimicrobial resistant (AMR) bacteria. Its anti-toxin monoclonal antibody (mAb) approach is a proven mechanism of action and has shown preliminary trend toward efficacy as an adjunctive therapy in reducing acute pneumonia patients time in ICU as compared to the current standard of care, which is antibiotics. In addition to its phase 3 program, ARDS also has a phase 2 asset for the treatment of Bacteria HAP/VAP LPS 011. The company also has an on-going phase 2 clinical trial for the treatment of Cystic Fibrosis patients, a program funded by the Cystic Fibrosis Foundation for $7.5 million. Importantly, ARDS is also preparing to launch a Phase 1/2 clinical trial in the second half of 2021 with a self-administered broadly neutralizing mAb for emerging COVID-19 mutated variants. The expansion of COVID virus strain coverage, combined with the product's self-administered, at-home treatment modality, further differentiates the company's AR-712 COVID treatment offering.
The document provides an update on Chesapeake Energy's proposed acquisition of WildHorse Resource Development Corporation. It discusses how the acquisition will accelerate Chesapeake's strategic plan by increasing margins, cash flow generation, and oil production. The acquisition adds a significant Eagle Ford asset to Chesapeake's portfolio and is expected to improve the company's financial and operational metrics. Cost savings of $200-280 million annually from operational and capital efficiencies are estimated to total $1-1.5 billion over five years. The combined company will have a diversified portfolio of oil and gas assets across multiple basins with significant high-margin oil growth potential.
Catasys provides a virtual, scalable, and data-driven behavioral health program called OnTrak to help address the high costs of untreated behavioral health conditions like substance abuse, depression, and anxiety. OnTrak uses predictive analytics to identify avoidant patients, engages them in a 52-week outpatient treatment program with care coaching support, and integrates medical and psychosocial care. This approach aims to reduce health plan costs by around 50% while providing full reimbursement. Catasys has signed agreements with several major health insurance companies to provide OnTrak and is seeing growing enrollment.
Valeant Pharmaceuticals International, Inc. revised its offer to acquire Allergan, Inc. on June 2, 2014. The revised offer provides Allergan shareholders $72 per share in cash and 0.83 shares of Valeant stock for each Allergan share. Pershing Square Capital Management, a large shareholder in both companies, agreed to accept only Valeant stock for its Allergan shares at a discounted price in order to provide more cash consideration to other Allergan shareholders. The revised offer is superior to the standalone value of Allergan and provides substantial synergies that increase the pro forma cash earnings per share of the combined company by approximately 25%.
Valeant reported strong financial results for Q1 2014, with product sales increasing 78% year-over-year to $1.85 billion and adjusted cash flow from operations growing 84% to $636 million. Organic growth was positive across regions and business units, led by dermatology, contact lenses, and ophthalmology in the US. Valeant remains active in business development, with over 20 transactions expected to close in 1H 2014. The company provided an update on its offer to acquire Allergan, noting overwhelmingly positive feedback from shareholders of both companies regarding the strategic benefits of the combination. Valeant intends to request information from Allergan and potentially pursue actions to engage the board or remove members to
Valeant Pharmaceuticals International, Inc. proposed acquiring Allergan, Inc. to create an unrivaled platform for growth and value creation in healthcare. The document outlines that the combination would be strategically and financially compelling for both companies' shareholders by creating significant earnings and share price accretion. It also defends Valeant against erroneous statements about its financials and operating model made by Allergan and short sellers. Valeant remains committed to pursuing the deal, which it believes both sets of shareholders should have the opportunity to vote on.
Valeant Pharmaceuticals proposes acquiring Allergan in an unrivaled platform for growth in healthcare. The transaction offers a substantial premium to Allergan shareholders and is expected to generate $2.7 billion or more in annual cost synergies. It would create an unrivaled portfolio in ophthalmology, dermatology, and aesthetics. Valeant has committed financing and there are no antitrust issues, allowing the transaction to close with sustainable long-term value for shareholders of the combined company.
Virios Therapeutics is a clinical-stage biotechnology company focused on advancing novel, dual mechanism antiviral therapies to treat conditions associated with virally triggered or maintained immune responses, such as Fibromyalgia (“FM”). Immune responses related to the activation of tissue resident Herpes Simplex Virus-1 (“HSV-1”) have been postulated as a potential root cause triggering and/or sustaining chronic illnesses such as FM, irritable bowel disease (“IBS”), and chronic fatigue syndrome, all of which can be characterized by waxing and waning symptom flare-ups with no obvious etiology. Virios’ lead development candidate (“IMC-1”) is a novel, proprietary, fixed dose combination of famciclovir and celecoxib designed to synergistically suppress HSV-1 replication, with the end goal of reducing virally promoted disease symptoms.
Prophecy Resources Corp is developing the 600 MW Chandgana power plant in Mongolia to help meet the country's growing energy demand. The Chandgana project has over 1.2 billion tonnes of thermal coal resources and all necessary construction permits. The mine-mouth power plant is fully permitted and would be the first of its kind in Mongolia. It is strategically located near energy infrastructure and markets in China and Russia. Successful development of the 600 MW Phase I plant would help address Mongolia's current power shortages and reliance on imports.
The document is a presentation about representing the 600 MW Chandgana power plant project. It provides background information and disclaimers, noting that the information is subject to changes and updates. It warns that the communication of the presentation does not constitute a commitment to any transaction. It also contains forward-looking statements about the development and production of the power plant, but warns that actual results could differ due to risks and uncertainties in the mining industry.
Aridis Pharmaceuticals is a late-stage clinical development company, leading the creation of transformative, first-in-class anti-infectives for life-threatening viral and bacterial respiratory infections. The company’s lead drug candidate for acute pneumonia met the primary endpoint for its phase 2 clinical trial and the Company is now enrolling in a global phase 3 study. Its pipeline of novel mechanism antibacterial and antivirals, sprung from its proprietary discovery technology platforms, are designed to combat the growing public health threat of viral pandemics and antimicrobial resistant (AMR) bacteria. Its anti-toxin monoclonal antibody (mAb) approach is a proven mechanism of action and has shown preliminary trend toward efficacy as an adjunctive therapy in reducing acute pneumonia patients time in ICU as compared to the current standard of care, which is antibiotics. In addition to its phase 3 program, ARDS also has a phase 2 asset for the treatment of Bacteria HAP/VAP LPS 011. The company also has an on-going phase 2 clinical trial for the treatment of Cystic Fibrosis patients, a program funded by the Cystic Fibrosis Foundation for $7.5 million. Importantly, ARDS is also preparing to launch a Phase 1/2 clinical trial in the second half of 2021 with a self-administered broadly neutralizing mAb for emerging COVID-19 mutated variants. The expansion of COVID virus strain coverage, combined with the product's self-administered, at-home treatment modality, further differentiates the company's AR-712 COVID treatment offering.
CanniMed Therapeutics Inc. is a leader in the Canadian medical cannabis industry and the first mover in international markets. It has a 15-year history of growing pharmaceutical-grade cannabis and is well positioned for growth through new distribution channels in Canada, increasing production capacity, and pursuing exports to multiple countries. Recent developments include strong Q3 2017 results, entering Canada's first pharmacy distribution agreement, and commencing an expansion of its Cannabis Oils Facility.
This presentation discusses MedReleaf's position as the leading Canadian medical cannabis producer. It highlights MedReleaf's quality assurance processes, patient-centric approach, analytical operations, and ongoing innovation in producing premium cannabis. MedReleaf also discusses its market leading position with 82% market share, low production costs of $1.49 per gram, and high adjusted product contribution margins of 19%. The presentation outlines MedReleaf's expansion plans and growth opportunities in medical, new products, recreational, and international markets.
This presentation provides background information on Wellgreen Platinum Ltd. and its Wellgreen platinum project. Some key points:
- The information is for general informational purposes only and has not been independently verified. No representations or warranties are given as to the accuracy or completeness of the information.
- The presentation does not constitute an offer to sell securities or a solicitation to purchase securities.
- Certain statements are forward-looking and actual results may differ materially from expectations due to various risks and uncertainties.
- Technical information is based on technical reports prepared according to NI 43-101 standards and available on SEDAR. The technical reports should be read in their entirety.
Catasys provides an integrated virtual healthcare program called OnTrak that identifies and treats behavioral health conditions like substance abuse and depression. OnTrak uses predictive analytics to identify high-cost patients with behavioral health issues who rarely seek treatment. Patients enroll in a 52-week virtual treatment program with care coaching support. Studies show OnTrak significantly reduces medical costs and healthcare utilization for enrolled members. Catasys contracts with health plans to provide OnTrak and is paid a monthly fee per enrolled member.
The document is a presentation by Wellgreen Platinum Ltd providing information on its Wellgreen platinum project in Yukon, Canada. It summarizes key details of the project including its large scale polymetallic deposit containing nickel, copper, platinum group metals and other metals, the 2014 mineral resource estimate showing over 5 billion pounds of nickel and copper in the measured and indicated categories, and the positive 2015 preliminary economic assessment showing over $1.2 billion post-tax NPV with a 3.1 year payback. The presentation also outlines the company's strong financial position, management team with extensive experience in project development and operations, and district scale exploration potential.
This document provides background information on Wellgreen Platinum Ltd. and its Wellgreen platinum project. It discusses the large-scale polymetallic deposit containing platinum group metals (PGMs), nickel, copper, cobalt, and gold. The 2014 mineral resource estimate outlines 330 million tonnes of measured and indicated resources containing over 5.5 million ounces of PGMs and 4.9 billion pounds of nickel and copper. An 2015 preliminary economic assessment outlined an open-pit mine with average annual production of 209,000 ounces of PGMs and 128 million pounds of nickel and copper over a 16-year mine life at costs in the lowest quartile. The project benefits from excellent infrastructure and year-round operations in Canada's Yukon
The document provides background information on Wellgreen Platinum Ltd., a company developing the Wellgreen platinum group metals (PGM) project in Canada. It discusses the large-scale polymetallic deposit, noting its significant PGM component with a platinum to palladium ratio of 1:1 that is open pittable. The document also highlights the project's proximity to LNG power, lack of endangered species, strong government and First Nations support, and the critical nature and growing demand for its metals including nickel, PGMs, copper, gold, cobalt, and lithium which are used in batteries, aerospace, power plants, stainless steel, construction, electronics, green technology, and jewelry. It provides an overview of the
HR Compliance & Insurance Benefit Perspectives: What Employers Should Be Awar...Rea & Associates
Guidelines for employees are constantly changing but it’s important that businesses stay on top of mandates and regulations. What risks should organizations be informed about? Is your organization able to have varied insurance premiums for vaccinated vs. non-vaccinated employees?
Join Rea & Associates and Huntington Insurance for a deep dive into best practices for exposures, insurance perspectives, and vaccine mandates and regulations.
EcoStim is an oilfield services company providing well stimulation services in the US and Argentina. The presentation highlights:
1) EcoStim has secured multiple new contracts in 2017 anchoring a second crew in the US and a long-term contract in Argentina, positioning it for accelerated growth.
2) EcoStim trades at an attractive valuation compared to peers based on enterprise value per hydraulic horsepower.
3) EcoStim utilizes proprietary downhole diagnostic and predictive technologies to more efficiently target completion stages, reducing costs for customers.
The document is a prospectus for Atech Holdings Ltd regarding its acquisition of Fatfish Internet Pte Ltd and Fatfish Capital Ltd (together "Fatfish Group"). Key points include:
- Atech will acquire 100% of Fatfish Internet and 50% of Fatfish Capital for $18 million in new shares and options.
- Fatfish Group is an IT investments group focused on Southeast Asian startups and growth companies.
- The acquisition will change Atech's focus to IT investments in Southeast Asia and require it to recomply with ASX listing rules.
- Atech aims to grow Fatfish Group's existing e-commerce brands and assess new investment opportunities upon relisting.
Interpace Diagnostics provides molecular diagnostic tests and pathology services to evaluate cancer risk. The presentation discusses:
1) Interpace's product portfolio including tests that risk-stratify pancreatic cysts, Barrett's esophagus, and thyroid nodules.
2) Clinical evidence and guidelines supporting their tests, and growth in adoption and coverage by payers.
3) Financial highlights including recent funding raises, revenue growth, and progress reducing costs.
4) Drivers for continued growth including expanding sales force and strategic partnerships.
Aridis Pharmaceuticals is a late-stage clinical development company, leading the creation of transformative, first-in-class anti-infectives for life-threatening viral and bacterial respiratory infections. The company’s lead drug candidate for acute pneumonia met the primary endpoint for its phase 2 clinical trial and the Company is now enrolling in a global phase 3 study. Its pipeline of novel mechanism antibacterial and antivirals, sprung from its proprietary discovery technology platforms, are designed to combat the growing public health threat of viral pandemics and antimicrobial resistant (AMR) bacteria. Its anti-toxin monoclonal antibody (mAb) approach is a proven mechanism of action and has shown preliminary trend toward efficacy as an adjunctive therapy in reducing acute pneumonia patients time in ICU as compared to the current standard of care, which is antibiotics. In addition to its phase 3 program, ARDS also has a phase 2 asset for the treatment of Bacteria HAP/VAP LPS 011. The company also has an on-going phase 2 clinical trial for the treatment of Cystic Fibrosis patients, a program funded by the Cystic Fibrosis Foundation for $7.5 million. Importantly, ARDS is also preparing to launch a Phase 1/2 clinical trial in the second half of 2021 with a self-administered broadly neutralizing mAb for emerging COVID-19 mutated variants. The expansion of COVID virus strain coverage, combined with the product's self-administered, at-home treatment modality, further differentiates the company's AR-712 COVID treatment offering.
The document provides an update on Chesapeake Energy's proposed acquisition of WildHorse Resource Development Corporation. It discusses how the acquisition will accelerate Chesapeake's strategic plan by increasing margins, cash flow generation, and oil production. The acquisition adds a significant Eagle Ford asset to Chesapeake's portfolio and is expected to improve the company's financial and operational metrics. Cost savings of $200-280 million annually from operational and capital efficiencies are estimated to total $1-1.5 billion over five years. The combined company will have a diversified portfolio of oil and gas assets across multiple basins with significant high-margin oil growth potential.
Catasys provides a virtual, scalable, and data-driven behavioral health program called OnTrak to help address the high costs of untreated behavioral health conditions like substance abuse, depression, and anxiety. OnTrak uses predictive analytics to identify avoidant patients, engages them in a 52-week outpatient treatment program with care coaching support, and integrates medical and psychosocial care. This approach aims to reduce health plan costs by around 50% while providing full reimbursement. Catasys has signed agreements with several major health insurance companies to provide OnTrak and is seeing growing enrollment.
Valeant Pharmaceuticals International, Inc. revised its offer to acquire Allergan, Inc. on June 2, 2014. The revised offer provides Allergan shareholders $72 per share in cash and 0.83 shares of Valeant stock for each Allergan share. Pershing Square Capital Management, a large shareholder in both companies, agreed to accept only Valeant stock for its Allergan shares at a discounted price in order to provide more cash consideration to other Allergan shareholders. The revised offer is superior to the standalone value of Allergan and provides substantial synergies that increase the pro forma cash earnings per share of the combined company by approximately 25%.
Valeant reported strong financial results for Q1 2014, with product sales increasing 78% year-over-year to $1.85 billion and adjusted cash flow from operations growing 84% to $636 million. Organic growth was positive across regions and business units, led by dermatology, contact lenses, and ophthalmology in the US. Valeant remains active in business development, with over 20 transactions expected to close in 1H 2014. The company provided an update on its offer to acquire Allergan, noting overwhelmingly positive feedback from shareholders of both companies regarding the strategic benefits of the combination. Valeant intends to request information from Allergan and potentially pursue actions to engage the board or remove members to
Valeant Pharmaceuticals International, Inc. proposed acquiring Allergan, Inc. to create an unrivaled platform for growth and value creation in healthcare. The document outlines that the combination would be strategically and financially compelling for both companies' shareholders by creating significant earnings and share price accretion. It also defends Valeant against erroneous statements about its financials and operating model made by Allergan and short sellers. Valeant remains committed to pursuing the deal, which it believes both sets of shareholders should have the opportunity to vote on.
Valeant Pharmaceuticals proposes acquiring Allergan in an unrivaled platform for growth in healthcare. The transaction offers a substantial premium to Allergan shareholders and is expected to generate $2.7 billion or more in annual cost synergies. It would create an unrivaled portfolio in ophthalmology, dermatology, and aesthetics. Valeant has committed financing and there are no antitrust issues, allowing the transaction to close with sustainable long-term value for shareholders of the combined company.
Valeant reported financial results for Q2 2014, with total revenue increasing 86% year-over-year to $2.041 billion. Organic growth accelerated significantly compared to Q1, though the sale of facial injectable assets reduced growth rates. Key highlights included FDA approval and launch of Jublia, three small acquisitions, and restructuring the Bausch + Lomb plant in Ireland. Valeant provided guidance for the remainder of 2014 and through 2016, expecting continued revenue and earnings growth. An update on the potential Allergan acquisition was also provided.
Valeant reported strong financial results for the third quarter of 2014, with total revenue growing 33% year-over-year to $2.1 billion and cash EPS growing 48% to $2.11. Several key business segments saw double-digit organic growth, including the recently acquired Bausch + Lomb business and emerging markets. Valeant also provided an update on its proposed acquisition of Allergan, noting potential regulatory hurdles and uncertainties remaining around a potential combination.
Prophecy Resources Corp is developing the 600 MW Chandgana power plant in Mongolia to help meet the country's growing energy demand. The Chandgana project has over 1.2 billion tonnes of thermal coal resources and all necessary construction permits. The mine-mouth power plant is fully permitted and would be the first of its kind in Mongolia. It is strategically located near energy infrastructure and markets in China and Russia. Successful development of the 600 MW Phase I plant would help address Mongolia's current power shortages and reliance on imports.
The document is a presentation about representing the 600 MW Chandgana power plant project. It provides background information and disclaimers, noting that the information is subject to changes and updates. It warns that the communication of the presentation does not constitute a commitment to any transaction. It also contains forward-looking statements about the development and production of the power plant, but warns that actual results could differ due to risks and uncertainties in the mining industry.
Valeant outlined its approach to growth through acquisitions and cost synergies in a presentation. It highlighted accelerating organic growth at acquired companies like Bausch + Lomb from 4% to over 10% through volume growth. Valeant also emphasized its output-driven R&D approach that has delivered more launches than competitors, and said it would deliver on Allergan's requirements at lower cost through a lean R&D model. The presentation concluded by noting Valeant's strong track record of capital deployment has generated superior returns on acquisitions.
The document provides a disclaimer and overview of information regarding the proposed 600 MW Chandgana power plant project in Mongolia. It notes that the information is for general background purposes and has not been independently verified. It warns that the information is subject to changes and updates, and disclaims any liability for inaccuracies or omissions. It also contains cautionary statements regarding forward-looking projections and the risks involved with the development of the power plant.
1. Prophecy Resources holds over 1.4 billion tonnes of coal resources across two properties in Mongolia.
2. It has secured all necessary permits to construct a mine-mouth power plant at its Chandgana deposit, located 150km from Mongolia's power grid.
3. The company's Ulaan Ovoo mine is currently producing coal, while its large Chandgana project has the potential to help meet Mongolia's growing energy needs and reduce its reliance on costly power imports from Russia.
This document provides an overview of Prophecy Resources Corp. and its plans to fulfill Asia's growing energy needs through developing the Chandgana Power Plant in Mongolia. It outlines key risks and uncertainties such as obtaining necessary permits and approvals, uncertainties around resource and reserve estimates, and risks associated with operating in foreign jurisdictions. The summary cautions that forward-looking statements are based on assumptions and actual results could differ due to disruptions or other factors.
Prophecy Resources Corp. is developing coal mines and a power plant in Mongolia to meet Asia's growing energy demands. The company owns two coal deposits totaling over 12 billion tons. It has obtained all necessary licenses to build a power plant near its mines, located only 120km from transmission lines. The management team has extensive experience developing large coal mines and power facilities. Investing in Prophecy provides exposure to Mongolia's booming resources sector near major economic growth centers with long-term energy needs.
Markforged provides an accessible, industrial-grade additive manufacturing solution through its integrated digital forge platform. It offers 3D printers and a variety of composite and metal materials that address a broad range of applications. Markforged has a large and growing total addressable market and projects strong revenue growth through 2025 as its customer base and number of connected printers increases.
Vintage Wine Estates (VWE) is a wine company owned by a group of vintner families with deep roots in the wine business.
Vintage Wine Estates built a portfolio of over 50 wine and spirits brands such as Viansa Sonoma and Napa Valley’s Girard from the California Wine County and the Pacific Northwest to grow into one of the largest U.S. wine producers.
VWE inked an agreement with a special-purpose acquisition company to become publicly trade with London-based Bespoke Capital Acquisition Corp. in a deal valued at $690M, plus $50M in future potential consideration.
VWE provides a comprehensive presentation that supersedes all prior presentations on the same topics. The presentation includes forward-looking statements, projections, and non-GAAP financial measures. It introduces VWE's experienced management team and track record of acquisitions. It also summarizes VWE's proposed combination with BCAC to become a public company.
Canadian Overseas Petroleum Limited is an international oil and gas exploration, development, and production company actively pursuing opportunities in the United States and in sub-Saharan Africa through its ShoreCan joint venture company in Nigeria, and independently in other countries.
COPL’s acquisition of Atomic Oil and Gas LLC and its affiliate companies in December 2020 has had a transformational impact on the group and is significantly value-enhancing. It provides an immediate and growing revenue stream and underpins the group’s strategic objectives.
We have a team of individuals who have many years of relevant industry experience and who possess a strong track record of making discoveries and bringing those to production. Our goal is to continue to expand our company by developing existing assets and securing discoveries. We specialize in exploiting oil assets in lightly explored emerging regions where large discoveries occur. We achieve this by focusing on single well-unappraised discoveries in these basins and evaluating them and bringing them into production quickly and efficiently.
COPL has a strong balance sheet, secure cash flow, and is now well placed to deliver increased production and enhanced revenues, profitability, and shareholder value.
Canadian Overseas Petroleum Limited: Investor Presentation - October 2022 CHF Investor Relations
COPL is an international oil and gas exploration, development and production
company actively pursuing opportunities in the United States with operations in
Converse County Wyoming, and in sub-Saharan Africa through its ShoreCan joint
venture company in Nigeria, and independently in other countries.
The Company’s Wyoming operations are one of the most environmentally responsible
with minimal gas flaring and methane emissions combined with electricity sourced
from a neighbouring wind farm to power production facilities.
Corporate presentation november 2016 finalcorpaveda2015
This corporate presentation provides an overview of Aveda Transportation and Energy Services Inc. It discusses Aveda's history of growth through acquisitions and expansion across North America. The presentation highlights Aveda's diversified revenue base across major oil basins in the US and Canada, as well as its blue chip customer base. It also summarizes Aveda's capitalization, balance sheet, and North American operations footprint.
Aveda Transportation and Energy Services Inc. presented its corporate strategy and outlook in January 2017. The presentation discussed Aveda's history of growth through acquisitions and expansion across North America since 1994. It highlighted Aveda's leadership team and board of directors with extensive oilfield experience. The presentation also noted Aveda's track record of revenue and adjusted EBITDA growth despite a 40% decline in rig counts from 2015 to 2016, demonstrating resilience in the downturn.
Similar to Pfizer Analyst and Investor Call to Discuss Proposed Combination with Allergan (20)
This document provides a summary of Johnson & Johnson's late stage pharmaceutical pipeline as of April 19, 2016. It lists products in cardiovascular, immunology, infectious diseases, neuroscience, and oncology therapeutic areas that are in Phase III development or registration in the US and EU. Key late stage programs include Darzalex for multiple myeloma, sirukumab for rheumatoid arthritis, guselkumab for psoriasis, esketamine for treatment resistant depression, and apalutamide for prostate cancer. The table also highlights recent US and EU approvals from 2015-2016 as well as planned filings from 2015-2019.
Johnson & Johnson Pharmaceutical Business ReviewDeepa K
The document is an agenda for an investor presentation. It outlines the schedule for the day which includes presentations on the company's enterprise overview, pharmaceutical commercial and R&D strategies, and various therapeutic areas. It also includes notices about forward-looking statements and new molecular entities being discussed. The speakers and locations are listed next to each topic.
Merck & Co., Inc. at 34th Annual J.P. Morgan Healthcare ConferenceDeepa K
Ken Frazier, CEO of Merck & Co., presented at the 2016 JPMorgan Healthcare Conference. He discussed Merck's strategy of adapting, innovating, and executing to create long-term value as a research-intensive biopharmaceutical company. Merck has a rich history of breakthrough products and has several recent approvals and ongoing trials. Merck will continue investing in its robust pipeline, pursuing the most promising science to address unmet medical needs through business development deals and internal research. Potential catalysts in 2016 include data readouts, regulatory filings, and approvals for products like Keytruda and treatments for hepatitis C.
Merck & Co., Inc. at UBS Global Healthcare ConferenceDeepa K
Merck provided an overview of its business and outlook for 2015. Key points include:
1) Merck reported Q1 2015 global sales of $9.4 billion, with pharmaceutical sales up 5% and animal health up 13%.
2) Merck is focused on four key growth platforms: diabetes, vaccines, hospital acute care, and oncology.
3) Merck has several new product launches underway or planned for 2015 in these core areas, including KEYTRUDA, BELSOMRA, GARDASIL9, and ZERBAXA.
4) Merck's pipeline includes late-stage programs in areas with large unmet needs like hepatitis C, atherosclerosis,
Merck @ JP MORGAN 2016 HEALTHCARE CONFERENCEDeepa K
Ken Frazier, CEO of Merck & Co., presented at the 2016 JPMorgan Healthcare Conference. He discussed Merck's strategy of adapting, innovating, and executing to create long-term value as a research-intensive biopharmaceutical company. Merck has a rich history of breakthrough products and has several major approvals, filings, and data readouts anticipated in 2016 for drugs like Keytruda and their hepatitis C pipeline. Merck remains committed to pursuing innovative science to address unmet medical needs through internal research and business development partnerships.
04 connecting hungerandhealth_hilaryseligmanDeepa K
This document discusses the link between food insecurity and diabetes. It begins with an overview of diabetes, noting that type 2 diabetes is the most common form and is increasingly affecting low-income populations. Food insecurity is associated with higher rates of diabetes and poorer diabetes control. Factors like inconsistent access to affordable, healthy foods and high stress levels related to food insecurity can disrupt diabetes management and contribute to health issues. The document proposes community-based programs located in places like food pantries as a way to better engage vulnerable groups in diabetes screening, education, and care coordination activities to improve health outcomes.
Pfizer Analyst and Investor Call to Discuss Proposed Combination with AllerganDeepa K
Pfizer and Allergan announced plans to combine, creating a new global biopharmaceutical leader. The transaction is subject to approval by shareholders of both companies and regulators. If approved, it would create a larger company with increased research capabilities and diversified product portfolio. However, the companies cautioned that there are risks that the transaction may not be completed as planned or at all due to factors including failure to obtain regulatory approvals or shareholder support.
SATTA MATKA SATTA FAST RESULT KALYAN TOP MATKA RESULT KALYAN SATTA MATKA FAST RESULT MILAN RATAN RAJDHANI MAIN BAZAR MATKA FAST TIPS RESULT MATKA CHART JODI CHART PANEL CHART FREE FIX GAME SATTAMATKA ! MATKA MOBI SATTA 143 spboss.in TOP NO1 RESULT FULL RATE MATKA ONLINE GAME PLAY BY APP SPBOSS
Top mailing list providers in the USA.pptxJeremyPeirce1
Discover the top mailing list providers in the USA, offering targeted lists, segmentation, and analytics to optimize your marketing campaigns and drive engagement.
IMPACT Silver is a pure silver zinc producer with over $260 million in revenue since 2008 and a large 100% owned 210km Mexico land package - 2024 catalysts includes new 14% grade zinc Plomosas mine and 20,000m of fully funded exploration drilling.
LA HUG - Video Testimonials with Chynna Morgan - June 2024Lital Barkan
Have you ever heard that user-generated content or video testimonials can take your brand to the next level? We will explore how you can effectively use video testimonials to leverage and boost your sales, content strategy, and increase your CRM data.🤯
We will dig deeper into:
1. How to capture video testimonials that convert from your audience 🎥
2. How to leverage your testimonials to boost your sales 💲
3. How you can capture more CRM data to understand your audience better through video testimonials. 📊
Discover timeless style with the 2022 Vintage Roman Numerals Men's Ring. Crafted from premium stainless steel, this 6mm wide ring embodies elegance and durability. Perfect as a gift, it seamlessly blends classic Roman numeral detailing with modern sophistication, making it an ideal accessory for any occasion.
https://rb.gy/usj1a2
The 10 Most Influential Leaders Guiding Corporate Evolution, 2024.pdfthesiliconleaders
In the recent edition, The 10 Most Influential Leaders Guiding Corporate Evolution, 2024, The Silicon Leaders magazine gladly features Dejan Štancer, President of the Global Chamber of Business Leaders (GCBL), along with other leaders.
Unveiling the Dynamic Personalities, Key Dates, and Horoscope Insights: Gemin...my Pandit
Explore the fascinating world of the Gemini Zodiac Sign. Discover the unique personality traits, key dates, and horoscope insights of Gemini individuals. Learn how their sociable, communicative nature and boundless curiosity make them the dynamic explorers of the zodiac. Dive into the duality of the Gemini sign and understand their intellectual and adventurous spirit.
Event Report - SAP Sapphire 2024 Orlando - lots of innovation and old challengesHolger Mueller
Holger Mueller of Constellation Research shares his key takeaways from SAP's Sapphire confernece, held in Orlando, June 3rd till 5th 2024, in the Orange Convention Center.
Digital Transformation and IT Strategy Toolkit and TemplatesAurelien Domont, MBA
This Digital Transformation and IT Strategy Toolkit was created by ex-McKinsey, Deloitte and BCG Management Consultants, after more than 5,000 hours of work. It is considered the world's best & most comprehensive Digital Transformation and IT Strategy Toolkit. It includes all the Frameworks, Best Practices & Templates required to successfully undertake the Digital Transformation of your organization and define a robust IT Strategy.
Editable Toolkit to help you reuse our content: 700 Powerpoint slides | 35 Excel sheets | 84 minutes of Video training
This PowerPoint presentation is only a small preview of our Toolkits. For more details, visit www.domontconsulting.com
Best practices for project execution and deliveryCLIVE MINCHIN
A select set of project management best practices to keep your project on-track, on-cost and aligned to scope. Many firms have don't have the necessary skills, diligence, methods and oversight of their projects; this leads to slippage, higher costs and longer timeframes. Often firms have a history of projects that simply failed to move the needle. These best practices will help your firm avoid these pitfalls but they require fortitude to apply.
In the Adani-Hindenburg case, what is SEBI investigating.pptxAdani case
Adani SEBI investigation revealed that the latter had sought information from five foreign jurisdictions concerning the holdings of the firm’s foreign portfolio investors (FPIs) in relation to the alleged violations of the MPS Regulations. Nevertheless, the economic interest of the twelve FPIs based in tax haven jurisdictions still needs to be determined. The Adani Group firms classed these FPIs as public shareholders. According to Hindenburg, FPIs were used to get around regulatory standards.
Part 2 Deep Dive: Navigating the 2024 Slowdownjeffkluth1
Introduction
The global retail industry has weathered numerous storms, with the financial crisis of 2008 serving as a poignant reminder of the sector's resilience and adaptability. However, as we navigate the complex landscape of 2024, retailers face a unique set of challenges that demand innovative strategies and a fundamental shift in mindset. This white paper contrasts the impact of the 2008 recession on the retail sector with the current headwinds retailers are grappling with, while offering a comprehensive roadmap for success in this new paradigm.
At Techbox Square, in Singapore, we're not just creative web designers and developers, we're the driving force behind your brand identity. Contact us today.
Industrial Tech SW: Category Renewal and CreationChristian Dahlen
Every industrial revolution has created a new set of categories and a new set of players.
Multiple new technologies have emerged, but Samsara and C3.ai are only two companies which have gone public so far.
Manufacturing startups constitute the largest pipeline share of unicorns and IPO candidates in the SF Bay Area, and software startups dominate in Germany.
Pfizer Analyst and Investor Call to Discuss Proposed Combination with Allergan
1. Pfizer and Allergan to Combine
Creating a New Global Biopharmaceutical
Leader
November 23, 2015
2. Information Related to This Communication
NO OFFER OR SOLICITATION
This communication is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation
to purchase or subscribe for any securities or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or
transfer of securities in any jurisdiction in contravention of applicable law.
This communication is not intended to be and is not a prospectus for the purposes of Part 23 of the Companies Act 2014 of Ireland (the “2014
Act”), Prospectus (Directive 2003/71/EC) Regulations 2005 (S.I. No. 324 of 2005) of Ireland (as amended from time to time) or the Prospectus
Rules issued by the Central Bank of Ireland pursuant to section 1363 of the 2014 Act, and the Central Bank of Ireland (“CBI”) has not approved
this communication.
IMPORTANT ADDITIONAL INFORMATION WILL BE FILED WITH THE SEC
In connection with the proposed transaction between Pfizer Inc. (“Pfizer”) and Allergan plc (“Allergan”), Allergan will file with the U.S. Securities
and Exchange Commission (the “SEC”) a registration statement on Form S-4 that will include a Joint Proxy Statement of Pfizer and Allergan that
also constitutes a Prospectus of Allergan (the “Joint Proxy Statement/Prospectus”). Pfizer and Allergan plan to mail to their respective
shareholders the definitive Joint Proxy Statement/Prospectus in connection with the transaction. INVESTORS AND SECURITY HOLDERS OF
PFIZER AND ALLERGAN ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS
FILED OR TO BE FILED WITH THE SEC CAREFULLY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT
INFORMATION ABOUT PFIZER, ALLERGAN, THE TRANSACTION AND RELATED MATTERS. Investors and security holders will be able to
obtain free copies of the Joint Proxy Statement/Prospectus (when available) and other documents filed with the SEC by Pfizer and Allergan
through the website maintained by the SEC at www.sec.gov. In addition, investors and security holders will be able to obtain free copies of the
documents filed with the SEC by Pfizer by contacting Pfizer Investor Relations at Bryan.Dunn@pfizer.com or by calling (212) 733-8917, and will
be able to obtain free copies of the documents filed with the SEC by Allergan by contacting Allergan Investor Relations at
investor.relations@actavis.com or by calling (862) 261-7488.
PARTICIPANTS IN THE SOLICITATION
Pfizer, Allergan and certain of their respective directors, executive officers and employees may be considered participants in the solicitation of
proxies in connection with the proposed transaction. Information regarding the persons who may, under the rules of the SEC, be deemed
participants in the solicitation of the respective shareholders of Pfizer and Allergan in connection with the proposed transactions, including a
description of their direct or indirect interests, by security holdings or otherwise, will be set forth in the Joint Proxy Statement/Prospectus when it is
filed with the SEC. Information regarding Pfizer’s directors and executive officers is contained in Pfizer’s proxy statement for its 2015 annual
meeting of stockholders, which was filed with the SEC on March 12, 2015, and certain of Pfizer’s Current Reports on Form 8-K. Information
regarding Allergan’s directors and executive officers is contained in Allergan’s proxy statement for its 2015 annual meeting of shareholders, which
was filed with the SEC on April 24, 2015, and certain of Allergan’s Current Reports on Form 8-K.
2
3. Forward-Looking Statements
Pfizer Cautionary Statement Regarding Forward-Looking Statements
This communication contains certain forward-looking statements with respect to the proposed transaction between Pfizer and Allergan. These
forward-looking statements can be identified by the fact that they do not relate only to historical or current facts. Forward-looking statements often
use future dates or words such as “anticipate”, “target”, “possible”, potential”, “predict”, “project”, “forecast”, “outlook”, “guidance”, “expect”,
“estimate”, “intend”, “plan”, “goal”, “believe”, “hope”, “aim”, “continue”, “will”, “may”, “might”, “would”, “could” or “should” or other words, phrases or
expressions of similar meaning or the negative thereof. Such forward-looking statements include, but are not limited to, statements about the
benefits of the proposed transaction, including anticipated future financial and operating results, synergies, accretion and growth rates, Pfizer’s,
Allergan’s and the combined company’s plans, objectives, expectations, intentions and anticipated financial results, plans relating to share
repurchases and dividends, and the expected timing of completion of the transaction. There are several factors which could cause actual plans
and results to differ materially from those expressed or implied in forward-looking statements. Such factors include, but are not limited to, the
failure to obtain necessary regulatory approvals (and the risk that such approvals may result in the imposition of conditions that could adversely
affect the combined company or the expected benefits of the transaction) and shareholder approvals or to satisfy any of the other conditions to
the transaction on a timely basis or at all, the occurrence of events that may give rise to a right of one or both of the parties to terminate the
merger agreement, adverse effects on the market price of Pfizer’s common stock and on Pfizer’s operating results because of a failure to
complete the transaction in the anticipated time frame or at all, failure to realize the expected benefits and synergies of the transaction,
restructuring in connection with the transaction and subsequent integration of Pfizer and Allergan, negative effects of the announcement or the
consummation of the transaction on the market price of Pfizer’s common stock and on Pfizer’s operating results, risks relating to the value of the
Allergan shares to be issued in the transaction, significant transaction costs and/or unknown liabilities, the risk of litigation and/or regulatory
actions, the loss of key senior management or scientific staff, general economic and business conditions that affect the companies following the
transaction, changes in global, political, economic, business, competitive, market and regulatory forces, future exchange and interest rates,
changes in tax and other laws, regulations, rates and policies, future business combinations or disposals, competitive developments, and the
uncertainties inherent in research and development. By their nature, forward-looking statements involve known and unknown risks and
uncertainties because they relate to events and depend on circumstances that will occur in the future. The factors described in the context of such
forward-looking statements in this communication could cause Pfizer’s plans with respect to Allergan, actual results, performance or
achievements, industry results and developments to differ materially from those expressed in or implied by such forward-looking statements.
Persons reading this communication are cautioned not to place undue reliance on these forward-looking statements which speak only as at the
date of this communication. Pfizer assumes no obligation to update or revise the information contained in this communication (whether as a result
of new information, future events or otherwise), except as required by applicable law. A further description of risks and uncertainties can be found
in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014 and in its subsequent reports on Form 10-Q, including in the
sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its
subsequent reports on Form 8-K, all of which are filed with the SEC and available at www.sec.gov and www.pfizer.com.
3
4. Forward-Looking Statements
Allergan Cautionary Statement Regarding Forward-Looking Statements
Statements contained in this communication that refer to Allergan’s anticipated future events, estimated or anticipated future results, or other non-
historical facts are forward-looking statements that reflect Allergan’s current perspective of existing trends and information as of the date of this
communication. Forward looking statements generally will be accompanied by words such as such as “anticipate”, “target”, “possible”, potential”,
“predict”, “project”, “forecast”, “outlook”, “guidance”, “expect”, “estimate”, “intend”, “plan”, “goal”, “believe”, “hope”, “aim”, “continue”, “will”, “may”,
“might”, “would”, “could” or “should” or other similar words, phrases or expressions or the negatives thereof. Such forward-looking statements
include, but are not limited to, statements about the benefits of the proposed transaction, including future financial and operating results and
synergies, Pfizer’s, Allergan’s and the combined company’s plans, objectives, expectations and intentions, and the expected timing of completion
of the transaction. It is important to note that Allergan’s goals and expectations are not predictions of actual performance. Actual results may differ
materially from Allergan’s current expectations depending upon a number of factors affecting Allergan’s business, Pfizer’s business and risks
associated with business combination transactions. These factors include, among others, the inherent uncertainty associated with financial
projections; restructuring in connection with, and successful closing of, the proposed transaction; subsequent integration of Pfizer and Allergan
and the ability to recognize the anticipated synergies and benefits of the proposed transaction; the ability to obtain required regulatory approvals
for the transaction (including the approval of antitrust authorities necessary to complete the transaction), the timing of obtaining such approvals
and the risk that such approvals may result in the imposition of conditions that could adversely affect the combined company or the expected
benefits of the transaction; the ability to obtain the requisite Pfizer and Allergan shareholder approvals; the risk that a condition to closing of the
proposed transaction may not be satisfied on a timely basis or at all; the failure of the proposed transaction to close for any other reason; risks
relating to the value of the Allergan shares to be issued in the transaction; the anticipated size of the markets and continued demand for Pfizer’s
and Allergan’s products; the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products
and pricing; market acceptance of and continued demand for Allergan’s and Pfizer’s products; difficulties or delays in manufacturing; the risks of
fluctuations in foreign currency exchange rates; the risks and uncertainties normally incident to the pharmaceutical industry, including product
liability claims and the availability of product liability insurance on reasonable terms; the difficulty of predicting the timing or outcome of pending or
future litigation or government investigations; periodic dependence on a small number of products for a material source of net revenue or income;
variability of trade buying patterns; changes in generally accepted accounting principles; risks that the carrying values of assets may be
negatively impacted by future events and circumstances; the timing and success of product launches; costs and efforts to defend or enforce
intellectual property rights; the availability and pricing of third party sourced products and materials; successful compliance with governmental
regulations applicable to Allergan’s and Pfizer’s facilities, products and/or businesses; changes in the laws and regulations affecting, among other
things, pricing and reimbursement of pharmaceutical products; risks associated with tax liabilities, or changes in U.S. federal or international tax
laws or interpretations to which they are subject, including the risk that the Internal Revenue Service disagrees that Allergan is a foreign
corporation for U.S. federal tax purposes; the loss of key senior management or scientific staff; and such other risks and uncertainties detailed in
Allergan’s periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan’s Annual Report on Form 10-
K for the year ended December 31, 2014, Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2015, Quarterly Report on
Form 10-Q for the quarterly period ended September 30, 2015, and from time to time in Allergan’s other investor communications. Except as
expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.
4
5. Irish Takeover Rules and Non-GAAP Financial Information
Applicability of the Irish Takeover Rules
As the transaction constitutes a "reverse takeover transaction" for the purposes of the Irish Takeover Panel Act, 1997, Takeover Rules, 2013, (the "Irish Takeover Rules"), Allergan is no longer in
an offer period and therefore Rule 8 of the Irish Takeover Rules does not apply to the transaction from the date of the announcement of the transaction and therefore there is no longer a
requirement to make dealing disclosures pursuant to Rule 8.
Statement Required by the Irish Takeover Rules
The directors of Pfizer accept responsibility for the information contained in this communication other than that relating to Allergan and the Allergan group of companies and the directors of
Allergan and members of their immediate families, related trusts and persons connected with them. To the best of the knowledge and belief of the directors of Pfizer (who have taken all
reasonable care to ensure that such is the case), the information contained in this communication for which they accept responsibility is in accordance with the facts and does not omit anything
likely to affect the import of such information.
The directors of Allergan accept responsibility for the information contained in this communication relating to Allergan and the directors of Allergan and members of their immediate families, related
trusts and persons connected with them. To the best of the knowledge and belief of the directors of Allergan (who have taken all reasonable care to ensure such is the case), the information
contained in this communication for which they accept responsibility is in accordance with the facts and does not omit anything likely to affect the import of such information.
Goldman Sachs International, which is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority in the United
Kingdom, and its affiliate, Goldman, Sachs & Co, are acting as joint financial adviser to Pfizer and no one else in connection with the proposed transaction. In connection with the proposed
transaction, Goldman Sachs International and Goldman, Sachs & Co, their affiliates and their respective partners, directors, officers, employees and agents will not regard any other person as their
client, nor will they be responsible to anyone other than Pfizer for providing the protections afforded to their clients or for giving advice in connection with the proposed transaction or any other
matter referred to in this announcement.
Guggenheim Securities, LLC is a broker dealer registered with the United States Securities and Exchange Commission and is acting as financial advisor to Pfizer and no one else in connection
with the proposed transaction. In connection with the proposed transaction, Guggenheim Securities, LLC, its affiliates and related entities and its and their respective partners, directors, officers,
employees and agents will not regard any other person as their client, nor will they be responsible to anyone other than Pfizer for providing the protections afforded to their clients or for giving
advice in connection with the proposed transaction or any other matter referred to in this announcement.
J.P. Morgan Limited (which conducts its UK investment banking business as J.P. Morgan Cazenove) (“J.P. Morgan”), which is authorised and regulated in the United Kingdom by the
Financial Conduct Authority, is acting as financial adviser exclusively for Allergan and no one else in connection with the matters set out in this announcement and will not regard any
other person as its client in relation to the matters in this announcement and will not be responsible to anyone other than Allergan for providing the protections afforded to clients of J.P.
Morgan or its affiliates, nor for providing advice in relation to any matter referred to herein.
Morgan Stanley & Co. LLC acting through its affiliate, Morgan Stanley & Co. International plc, is financial advisor to Allergan and no one else in connection with the matters referred to in this
announcement. In connection with such matters, Morgan Stanley & Co. LLC, Morgan Stanley & Co. International plc, each of their affiliates and each of their and their affiliates' respective
directors, officers, employees and agents will not regard any other person as their client, nor will they be responsible to any other person other than Allergan for providing the protections afforded
to their clients or for providing advice in connection with the contents of this announcement or any other matter referred to herein.
Unless otherwise defined, capitalised terms used in this Statement Required by the Irish Takeover Rules shall have the meaning given to them in the transaction-related press release issued by
Pfizer and Allergan on November 23, 2015.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE
RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.
5
Non-GAAP Financial Information
This presentation includes certain financial measures regarding Pfizer that were not prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). Any non-U.S. GAAP
financial measures presented should not be viewed as substitutes for financial measures required by U.S. GAAP, have no standardized meaning prescribed by U.S. GAAP and may not be
comparable to the calculation of similar measures of other companies.
6. Creating a New Global Biopharmaceutical Leader
6
Best-in-Class Businesses
• Bolsters top-tier innovative biopharma
business with leadership positions in new
therapeutic areas of growth
• Creates the world’s leading1 established
products business well-positioned for
global long-term growth
Enhances Growth Profile
• Strengthens top-line growth potential
• Deep pipeline of innovative therapies
• Opportunity for meaningful synergies
• Leverages experience of both
companies in integrating large
organizations
Increases Financial Flexibility
• Substantially improves access to cash for
investment in bringing new medicines to
patients and direct return to shareholders
• Increased flexibility better enables
continued investment in the U.S.
Preserves Future Optionality
• Allergan strategically fits with existing
Pfizer Innovative and Established
structure
• Improves growth durability and
financial flexibility of both businesses
1. Measured by revenue.
7. Innovative
Established
(Including Hospira)
2013-2015
Build two pharma
businesses with
distinct capabilities
Pfizer has Been on a Consistent Path to Create
Best-in-Class Innovative and Established Businesses
2015
Trademarks are the property of their respective owners and used for information purposes only.
2010-2013
Focus on core
pharma business and
unlock trapped value
Enhance Category Leadership
2015+
Optimize our two pharma
businesses while fully utilizing
enterprise capital structure
7
Nutritionals
Generate Sustainable Growth
Optimize Capital Structure
Leverage Global Scale
and Capabilities
8. Allergan Accelerates Pfizer’s Strategic Objectives
8
Enhance Category Leadership
Generate Sustainable Growth
Optimize Capital Structure
Leverage Global Scale
and Capabilities
Strong innovative category leadership with
durable flagship franchises built on
exceptional customer connections
Multiple drivers of innovative growth across
a broad mix of payer types
Potential revenue synergies driven by
durable product franchises that can benefit
from Pfizer’s global scale for growth
High degree of financial flexibility
9. A Strong Foundation From Which to Build
9
2015E
Pro Forma
Revenue
• ~$48 billion1
Powerful
Global
Capabilities
and Reach
• ~30,000 U.S. colleagues
• ~65,000 ex-U.S. colleagues
Enhanced
Innovative
Category
Leadership
• ~$16 billion2
• ~10,000 U.S. colleagues3
• ~5,000 ex-U.S. colleagues3
• Oncology
• Vaccines
• Cardio Metabolic
• Rare Diseases
• Inflammation &
Immunology
• Aesthetics & Dermatology
• Eye Care
• Neuroscience
1. Represents mid-point of Pfizer 2015 revenue guidance range issued on October 27, 2015. Please see Pfizer’s Current Report on Form 8-K dated October 27, 2015
and Quarterly Report on Form 10-Q for the fiscal quarter ended September 27, 2015 for assumptions and disclosures regarding Pfizer’s 2015 financial guidance.
2. Based on Allergan’s public disclosure dated July 27, 2015 for the remaining Allergan business pro forma for the pending divestiture of Allergan’s generic business to
Teva.
3. Pro forma for the pending divestiture of Allergan’s generic business to Teva.
10. Sustainable Growth
Platform with
Category Leadership
Capabilities in
Maximizing
Established Brands
Allergan is a Growth Pharma Leader
10
Double digit branded sales
growth1
Product line depth and category leadership
Productive investment in R&D through focus on
Open Science model
Highly-efficient SG&A spending
Experienced team committed
to success
Powerful global supply chain recognized as a
leader in customer service
Innovative Revenue
Growth2
Double Digit
Established Revenue
Growth2
Mid Single Digit
Source: EvaluatePharma and analyst consensus.
Note: Allergan figures are pro forma for the pending divestiture of Allergan’s generic business to Teva.
1. As disclosed in Allergan’s Q3 2015 Earnings release dated November 4, 2015.
2. Represents anticipated growth for 2016E – 2020E based on analyst estimates.
Characteristics that Define Our Exceptional Company
11. Allergan’s World-Renowned Brands
11
Women's Health
Other
(including CV)
Anti-Infectives
Urology
Eye Care
Aesthetics &
Dermatology
Neuroscience
GI
U.S. & Canada International
12. More Than 70 Mid-to-Late Stage Development
Opportunities in Key Therapeutic Areas
12
Skin Quattro Device
Delivery for
Facial Fillers
21
Aesthetics &
Dermatology
Oxymetazoline
Rosacea
Aczone Reform
Acne Vulgaris
Sarecycline
Acne
Juvederm
Global Nasal
Labial Folds
Vobella
Lips Fine Lines
Botox
Forehead
Lines
Volift
Nasolabial Folds
Voluma
Filler for Temple
Voluma Plus
Facial Volumes
Voluma Global
Malar Augmentation
Phoenix
Breast Augmentation
VoLite
Filler
Voluma
Filler for Chin
Oxybutynin
Hyperhidrosis
Bimatoprost
Androgenic
Alopecia
MT10109L
Aesthetics
Facial Lines
HA Threads
Forehead & Neck
Aczone Combo
Acne Vulgaris
Setipiprant
Androgenic Alopecia
Bimatoprost
Submental Fat
Reduction
Women’s Health
4 Estradiol
Vaginal Cream VVA &
Dyspareunia
Ulipristal
Fibroids
Estradiol
Vag Caps VVA
& Dyspareunia
Etonogestral Ring
Contraception
9
CNS
Rapastinel
MDD
AGN-241689
Migraine
Prophylaxis
Ubrogepant
Acute
Migraine
Botox
MDD
Vraylar
Multiple
Semprana
Acute Migraine
Vraylar
Bipolar Depression
Botox X
Spasticity
AGN-241660
MDD
9
Biosimilar X
Indication X
Nebivilol/Valsartan
Hypertension
Botox
Multiple
Bevacizumab
Multiple Cancer
Cetuximab
Multiple Cancer
Trastuzumab
Multiple Cancer
Rituximab
Non-Hodgkin
Lymphoma
TRV-027
Acute Heart Failure
Armour Thyroid
Hypothyroidism
Other
(Biosimilars, Cardiovascular and other)
Urology
4Botox
Premature
Ejaculation
LiRIS
Interstitial
Cystitis
SER-120
Adult Nocturia
Botox
Indication X
17
Eye
Care
Tripligan
(MMT) Ocular
HTN & Glaucoma
FPR2
Agonist Dry Eye
Disease
Mimetogen
Dry Eye
Bimatoprost SR
Glaucoma
Ganfort
MDPF
Restasis
MDPF
Omega 3 OTC
Dry Eye
Pilo/Oxy
Presbyopia
Cortisol Analog
Dry Eye Disease
Brimo DDS
Atrophic AMD
Androgen
Evaporative Dry Eye
Cyclosporine SR
Dry Eye
DARPin®
DME
Dual DARPin®
AMD
DARPin® SR
AMD
OCU Tearbud 1
Dry Eye
DARPin®
AMD
GI
Linzess
OIC
Linzess
Colonic
Release CIC
Linzess
Low Dose CIC
Viberzi
IBS-D
5
Relamorelin
Diabetic
Gastroparesis
Avycaz
cUTI, cIAI
5
Anti-Infective
Dalbavancin
Osteomyelitis
Dalbavancin
Endocarditis
Dalbavancin ABSSSI
Single Dose
Aztreonam /
Avibactam
Gram Neg Infect
Source: Allergan standalone pipeline information as of Allergan R&D Day on November 4, 2015.
13. Why Combination is Attractive for Allergan
Stakeholders
13
Accelerates strategy to move up the value chain and creates a new
leader in innovative biopharmaceuticals
Leverages long-term upside of enhanced combined innovative pipeline
Ability to leverage Pfizer’s global scale to maximize value of Allergan’s
leading innovative franchises
Delivers immediate, long-term value to Allergan shareholders and
continued shareholder returns (including dividends, buybacks)
Opportunity to continue delivering significant shareholder value through
enhanced scale, capabilities and operating synergies
14. Transaction Overview
14
Purchase
Price
Name and
Relative
Ownership
Shareholder
Consideration
• $160B transaction, based on 11.3 shares of the combined company for
each Allergan share, implying a price of $363.63 per Allergan share1
• Pfizer stockholders receive 1 share of the combined company for each
Pfizer share, or may elect to receive cash for some or all of their
Pfizer Inc. shares4
• Allergan shareholders receive ~4.7B3 shares of the combined company
as a result of an 11.3-for-1 share split
• Shares to remain NYSE listed and traded under the “PFE” ticker
• Pfizer and Allergan will be combined under the existing Allergan entity
and the continuing company will be called Pfizer plc2
• Pfizer stockholders will own ~56% of the combined company shares3
1. Allergan price per share based on Pfizer closing share price of $32.18 on November 20, 2015 and an assumed 11.3 for 1 split of Allergan shares.
2. Subject to shareholder vote.
3. Pro forma ownership is on a fully diluted basis assuming $12 billion cash paid and does not consider ordinary course buybacks.
4. Total cash paid in the merger will be a minimum of $6 billion and a maximum of $12 billion, and stock and cash elections will be subject to proration to ensure that at least
$6 billion and no more than $12 billion of cash is paid in the merger.
15. Transaction Overview – continued
15
The Combination is at an
Implied Price of $363.63 per Allergan Share1
Allergan increases amount of its authorized
share capital, and…
Allergan effects an 11.3-for-1 share split and
Allergan shareholders hold ~4.7B3 shares of the
combined company, which allows for…
Current Pfizer stockholders to receive ~5.9B3 new
shares of the combined company through a 1-for-1
share exchange, with the ability to elect to receive
cash in lieu of combined company shares4
1. Allergan price per share based on Pfizer closing share price of $32.18 on November 20, 2015 and an assumed 11.3 for 1 split of Allergan shares.
2. Subject to shareholder vote.
3. Pro forma ownership is on a fully diluted basis assuming $12 billion cash paid and does not consider ordinary course buybacks.
4. Total cash paid in the merger will be a minimum of $6 billion and a maximum of $12 billion, and stock and cash elections will be subject to proration to ensure that at least
$6 billion and no more than $12 billion of cash is paid in the merger.
Using Existing Irish Allergan TopCo
~56%3
~44%3
Pfizer plc
Combined Company
Renamed Pfizer plc2
Pro Forma
Ownership
Pro Forma
Ownership
1
2
3
16. Transaction Overview – continued
16
Location
Governance
Closing
• Global operational headquarters in New York
• Maintain Allergan’s Irish domicile
• Closing expected in the second half of 2016
• Subject to customary closing conditions, including Pfizer and Allergan
shareholder approvals and regulatory approvals, as well as completion of
Allergan’s pending divestiture to Teva
• Both companies have the right to terminate in specified circumstances with
termination fees of up to $3.5 billion
• Unanimously approved by both Boards
• Pfizer plc’s Board is expected to have 15 directors, consisting of all of
Pfizer’s 11 current directors and 4 current directors of Allergan, including
Allergan’s current Executive Chairman and Allergan’s current CEO
• Pfizer’s Chairman and CEO will serve as Chairman and CEO of the
combined company and Allergan’s CEO will serve as President and COO
17. Financial Highlights
17
• More than $2B in expected peak annual operating synergies
• Full synergies are projected to be achieved over the first 3 years post-close
Synergy
Capture
• Significantly expands access to cash, providing optimal financial flexibility,
including substantial continued investment in the U.S.
• Expect combined operating cash flow in excess of $25B beginning in 2018
• Expected pro forma adjusted effective tax rate1 to be approximately
17% – 18% by the first full year after closing
Enhanced
Financial
Flexibility
• Expected to be neutral to adjusted diluted EPS1 in 2017, modestly accretive
beginning in calendar year 2018, more than 10% accretive in 2019 and
high-teens percentage accretion in 20202
Compelling
Earnings
Accretion
Enhanced
Growth
Profile
• Enhances top- and bottom-line growth profile of both innovative and
established businesses
• Remain committed to attractive current dividend policy, targeting a
50% dividend payout ratio
Strong
Shareholder
Returns
1. Adjusted income and its components and adjusted diluted EPS are defined as U.S. GAAP reported net income and its components and U.S. GAAP reported diluted EPS
excluding purchase accounting adjustments, acquisition-related costs, discontinued operations and certain significant items.
2. Expectations include the impact of expected share repurchases following the transaction.
18. Vaccines
Best-in-Class Innovative Business
18
Oncology
Cardio
Metabolic
Rare Disease
Inflammation &
Immunology
Aesthetics &
Dermatology
Eye Care
Pfizer+Allergan
Expands Innovative Category Leadership With Strong Flagship Products
Projected to Generate Sustainable Innovative Growth
Diversifies portfolio
of payer types
Strengthens capabilities in
developing and sourcing
new molecular entities and
new indications
Adds portfolio of growing,
durable flagship franchises
Selected
Brands
Note: Investing in neuroscience R&D to position Pfizer for a category leadership position in the longer-term.
19. Top-Tier Growth Pharma Business Positioned for
Sustained Long-Term Leadership
19
2016E – 2020E Consensus1
Innovative Business Revenue CAGR
Expected Innovative Business Growth
Sustained by Strong Pipeline
1. Represents anticipated growth for 2016E – 2020E based on analyst estimates.
2. Represents combined pro forma Pfizer-Allergan innovative revenue. Assumes Pfizer’s Lyrica and Viagra are moved to Established Business given peri-LOE status.
2
Over 100 innovative mid-to-late stage
programs in clinical development
Bococizumab
New Products
New Indications
SelectedBrandsSelectedBrands
High Single Digit
Mid Single Digit
Avelumab
20. • Increased scale • Durable mature product franchises
in key therapeutic areas including
CV, neuroscience, pain, women’s
health and anti-infectives
• Managing peri-LOE products in
developed markets
• Leveraging Pfizer’s global scale to
drive strong emerging markets
growth across the portfolio
The World’s Leading1 Established Products Business
20
Pro Forma Scale and Complementary Capabilities
Maximize the Combined Established Products Portfolio
Combined Scale Combined Capabilities
Established Product
2015E Pro Forma Revenue
>$30BILLION
Source: EvaluatePharma and analyst estimates.
Note: Assumes Pfizer’s Lyrica and Viagra are moved to Established Business given peri-LOE status.
1. Measured by revenue.
21. Combined Proven Track Record of Successful Integration
21
Immediate focus on early integration planning
Will identify best-of-the-best of both organizations
Complementary corporate cultures will enable colleagues to
build upon mutual areas of expertise
Legacy businesses have a strong record of meeting and
exceeding synergy targets
Long History of Successful Integration
of Transformational Business Combinations